Vutrisiran shows long-term benefit in ATTR-CM Phase 3 study

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Alnylam Pharmaceuticals reported new data from its HELIOS-B Phase 3 study evaluating vutrisiran in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The company said results presented at the European Society of Cardiology (ESC) Congress 2025 demonstrated sustained cardiovascular benefit over a median of 36 months.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE